Literature DB >> 7495683

Immunohistochemical detection of early myocardial infarction. An evaluation of antibodies against the terminal complement complex (C5b-9).

E Edston1, K Kawa.   

Abstract

Antibodies (abs) against the terminal complement complex (C5b-9) were used on routinely processed post mortem myocardial tissue in parallel with conventional staining methods. Both monoclonal and polyclonal abs were tested using the avidin biotin peroxidase complex (ABC), alkaline phosphatase anti-alkaline phosphatase (APAAP) methods and an ab-bridge with alkaline phosphatase. Enhancement of the diaminobenzene (DAB) end product with cobalt-nickel (ABC method) was also done. The polyclonal ab gave the most satisfactory results and the alkaline phosphate conjugated ab-bridge had a slight advantage over the ABC method. Cobalt-nickel enhancement of DAB improved the visualization, but with higher background staining. APAAP was the least satisfactory method. Comparing the immunohistochemical method with the conventional staining methods, the former showed positive reaction in 97% of areas of coagulation necrosis and in 65% of contraction band necrosis. On the other hand coagulation necrosis was seen in 44% and contraction band necrosis in 68% of C5b-9 positive areas indicating that C5b-9 abs react with ischemically damaged myocytes before visible alterations are seen in hematoxilin-eosin staining. Moreover, using C5b-9 abs, it seems possible to exclude agonal/artefactual contraction bands which show a negative reaction. Immunohistochemical detection of C5b-9, using an adequate technique could increase the possibility to demonstrate early ischemic myocardial damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495683     DOI: 10.1007/bf01845613

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  13 in total

1.  Sudden coronary death. A postmortem study in 208 selected cases compared to 97 "control" subjects.

Authors:  G Baroldi; G Falzi; F Mariani
Journal:  Am Heart J       Date:  1979-07       Impact factor: 4.749

2.  Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow.

Authors:  R A Kloner; C E Ganote; D A Whalen; R B Jennings
Journal:  Am J Pathol       Date:  1974-03       Impact factor: 4.307

3.  Immunohistochemical detection of C5b-9(m) in myocardium: an aid in distinguishing infarction-induced ischemic heart muscle necrosis from other forms of lethal myocardial injury.

Authors:  H Thomsen; H Held
Journal:  Forensic Sci Int       Date:  1995-01-30       Impact factor: 2.395

4.  Morphologic effects of defibrillation: a preliminary report.

Authors:  S B Karch; M E Billingham
Journal:  Crit Care Med       Date:  1984-10       Impact factor: 7.598

5.  Heavy metal intensification of DAB-based HRP reaction product.

Authors:  J C Adams
Journal:  J Histochem Cytochem       Date:  1981-06       Impact factor: 2.479

6.  Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium.

Authors:  H Schäfer; D Mathey; F Hugo; S Bhakdi
Journal:  J Immunol       Date:  1986-09-15       Impact factor: 5.422

7.  Further evaluation of immunocytochemical staining in the diagnosis of early myocardial ischaemic/hypoxic damage.

Authors:  S Leadbeatter; H M Wawman; B Jasani
Journal:  Forensic Sci Int       Date:  1990-03       Impact factor: 2.395

8.  Immunocytochemical diagnosis of early myocardial ischaemic/hypoxic damage.

Authors:  S Leadbeatter; H M Wawman; B Jasani
Journal:  Forensic Sci Int       Date:  1989-02       Impact factor: 2.395

9.  The application of selected histochemical and immunohistochemical markers and procedures to the diagnosis of early myocardial damage.

Authors:  B Brinkmann; M A Sepulchre; G Fechner
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

10.  Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium.

Authors:  F Hugo; T Hamdoch; D Mathey; H Schäfer; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

View more
  7 in total

1.  Early markers for myocardial ischemia and sudden cardiac death.

Authors:  Sara Sabatasso; Patrice Mangin; Tony Fracasso; Milena Moretti; Mylène Docquier; Valentin Djonov
Journal:  Int J Legal Med       Date:  2016-07-08       Impact factor: 2.686

2.  Morphological identification of right ventricular failure in cases of fatal pulmonary thromboembolism.

Authors:  Tony Fracasso; Heidi Pfeiffer; Cristina Sauerland; Andreas Schmeling
Journal:  Int J Legal Med       Date:  2010-07-10       Impact factor: 2.686

3.  Multiplex quantitative imaging of human myocardial infarction by mass spectrometry-immunohistochemistry.

Authors:  Aleksandra Aljakna; Estelle Lauer; Sébastien Lenglet; Silke Grabherr; Tony Fracasso; Marc Augsburger; Sara Sabatasso; Aurélien Thomas
Journal:  Int J Legal Med       Date:  2018-03-19       Impact factor: 2.686

4.  Early markers of myocardial ischemia: from the experimental model to forensic pathology cases of sudden cardiac death.

Authors:  Sara Sabatasso; Milena Moretti; Patrice Mangin; Tony Fracasso
Journal:  Int J Legal Med       Date:  2017-05-11       Impact factor: 2.686

5.  High prevalence of acute myocardial damage in a hospital necropsy series, shown by C9 immunohistology.

Authors:  M A Ferreira; H E Owen; A J Howie
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

6.  Utility of desmin and a Masson's trichrome method to detect early acute myocardial infarction in autopsy tissues.

Authors:  Jie Ouyang; Miguel Guzman; Fidelina Desoto-Lapaix; Matthew R Pincus; Rosemary Wieczorek
Journal:  Int J Clin Exp Pathol       Date:  2009-09-20

7.  A theoretical timeline for myocardial infarction: immunohistochemical evaluation and western blot quantification for Interleukin-15 and Monocyte chemotactic protein-1 as very early markers.

Authors:  Emanuela Turillazzi; Marco Di Paolo; Margherita Neri; Irene Riezzo; Vittorio Fineschi
Journal:  J Transl Med       Date:  2014-07-02       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.